Stay updated on Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.

Latest updates to the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page
- Check6 days agoChange DetectedThese changes reflect updates to the study record's update history, with May 2026 timestamps added and April 2026 timestamps removed. They indicate edits to the page's metadata rather than changes to the study's design, eligibility, or outcomes.SummaryDifference0.1%

- Check13 days agoChange DetectedTwo trial sites were updated: Liuzhou, China (545026) and Taoyuan, Taiwan (33382) were added, while Liuchow, China (545026) and Taoyuan District, Taiwan (33382) were removed.SummaryDifference0.0%

- Check20 days agoChange DetectedThe page’s footer “Revision” indicator is updated from v3.5.2 to v3.5.3, reflecting a minor update to the site software/versioning without changing the displayed trial content.SummaryDifference0.0%

- Check27 days agoChange DetectedAdditions: 2026-04-13, 2026-04-09, 2026-04 and Revision: v3.5.2. Deletions: 2026-03-16, 2026-03-12, 2026-03 and Revision: v3.5.0.SummaryDifference0.1%

- Check42 days agoChange DetectedPadova, Italy, 35128 has been added to the locations and Padua, Italy, 35128 has been removed.SummaryDifference0.0%

- Check56 days agoChange DetectedRevision notes show the page updated to version 3.5.0 (2026-03-16) with related changes, and the earlier version 3.4.3 (2026-02-12) removed.SummaryDifference0.1%

Stay in the know with updates to Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.